6 completed, 4 unknown, 3 active not recruiting, 3 recruiting. 18 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 6, Unknown 4, Active not recruiting 3, Recruiting 3, Terminated 2 |
| Phase 1 | 2 | Unknown 2 |
| Phase 3 | 2 | Recruiting 1, Unknown 1 |
Follow Klatskin Tumor: new trials by email Literature Review of Klatskin Tumor trials Research Report on Klatskin Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma Pembrolizumab, Gemcitabine, Cisplatin - Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma | Phase 2 / Phase 3 | Recruiting | Amsterdam UMC, location VUmc | 150 | 2026-04-17 | 2026-08-25 |
| Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma Stereotactic Body Radiotherapy (SBRT), Tislelizumab, Gemcitabine - Cholangiocarcinoma, Hilar Cholangiocarcinoma | Phase 2 | Recruiting | Jinbo Yue | 38 | 2025-07-01 | 2026-10-15 |
| Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA Gemcitabine Oxaliplatin and 5FU - Intrahepatic Cholangiocarcinoma (Icc), Perihilar Cholangiocarcinoma | Phase 2 | Terminated | Peking University | 1 | 2024-12-31 | 2026-01-28 |
| Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer Capecitabine, Toripalimab - Gallbladder Cancer, Hilar Cholangiocarcinoma | Phase 2 | Active not recruiting | Tianjin Medical University Cancer Institute and Hospital | 110 | 2024-11-12 | 2024-12-05 |
| Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) Binimetinib, Biopsy Procedure, Biospecimen Collection - Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 18 | 2024-02-09 | 2026-11-12 |
| Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma | Phase 2 | Active not recruiting | University of Kansas Medical Center | 15 | 2024-02-01 | 2026-02-24 |
| PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma PD-1antibody plus GEMOX - Perihilar Cholangiocarcinoma | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 62 | 2023-01-31 | 2026-02-09 |
| Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer Durvalumab, Tremelimumab, Capecitabine - Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma | Phase 2 | Completed | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 40 | 2022-05-23 | 2025-05-01 |
| Biliary Drainage Plus HAIC in Locally Advanced pCCA oxaliplatin and 5-fluorouracil, Biliary Drainage, Best Supportive Care - Perihilar Cholangiocarcinoma | Phase 2 | Completed | Peking University | 127 | 2021-11-01 | 2025-12-18 |
| Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers Toripalimab plus Lenvatinib - Advanced Biliary Tract Cancer | Phase 2 | Unknown | Peking Union Medical College Hospital | 44 | 2020-08-11 | 2023-03-29 |
| Fluorescence Image Guided Surgery in Cholangiocarcinoma Bevacizumab-IRDye800CW, near infrared (NIR) fluorescence imaging - Hilar Cholangiocarcinoma | Phase 1 / Phase 2 | Unknown | University Medical Center Groningen | 12 | 2019-04-01 | 2021-04-28 |
| A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma ABC294640, Hydroxychloroquine Sulfate 200 MG - Cholangiocarcinoma, Cholangiocarcinoma Non-resectable | Phase 2 | Completed | RedHill Biopharma Limited | 65 | 2018-03-07 | 2025-07-23 |
| Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma PDT-Deuteporfin(6 hour), PDT-Deuteporfin(9 hour), stenting - Hilar Cholangiocarcinoma | Phase 2 | Terminated | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 7 | 2017-05-17 | 2019-07-17 |
| Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma bilateral metal stent insertion, unilateral metal stent insertion - Hilar Cholangiocarcinoma | Phase 2 / Phase 3 | Unknown | Air Force Military Medical University, China | 70 | 2014-07-01 | 2019-08-01 |
| Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers Temoporfin - Cholangiocarcinoma, Tumor | Phase 2 | Completed | Chinese University of Hong Kong | 10 | 2014-03-28 | 2023-08-22 |
| Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Capecitabine, Fluorouracil, Laboratory Biomarker Analysis - Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 53 | 2014-02-01 | 2017-09-12 |
| Safety Study of Liver Transplantation for Hilar Cholangiocarcinoma liver transplantation combined with neoadjuvant therapy - Hilar Cholangiocarcinoma | Phase 1 / Phase 2 | Unknown | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 60 | 2013-05-01 | 2014-06-30 |
| Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Erlotinib Hydrochloride, Sorafenib Tosylate - Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2010-04-01 | 2015-06-30 |
Cholangiocarcinoma (11) · Gallbladder Neoplasms (6) · Bile Duct Neoplasms (3) · Biliary Tract Neoplasms (2) · Carcinoma, Hepatocellular (1) · Cirrhosis, Familial, with Pulmonary Hypertension (1) · Jaundice (1) · Neoplasms (1)
Adenocarcinoma (18) · Carcinoma (18) · Neoplasms by Histologic Type (18) · Neoplasms, Glandular and Epithelial (18) · Neoplasms (17) · Biliary Tract Diseases (7) · Cholangiocarcinoma (7) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Neoplasms by Site (7) · Gallbladder Diseases (6) · Biliary Tract Neoplasms (5) · Bile Duct Diseases (3) · Hyperbilirubinemia (1) · Liver Diseases (1)
Fluorouracil (4) · Capecitabine (3) · Oxaliplatin (3) · Biopsy (2) · Cisplatin (2) · Gemcitabine (2) · Leucovorin (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · dehydroftorafur (2) · toripalimab (2) · 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (1) · Erlotinib Hydrochloride (1) · Hydroxychloroquine (1) · Neoadjuvant Therapy (1)
National Cancer Institute (NCI) (3) · Peking University (2) · Air Force Military Medical University, China (1) · Amsterdam UMC, location VUmc (1) · Chinese University of Hong Kong (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Jinbo Yue (1) · Peking Union Medical College Hospital (1) · RedHill Biopharma Limited (1) · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · Tianjin Medical University Cancer Institute and Hospital (1) · University Medical Center Groningen (1) · University of Kansas Medical Center (1)
China (9) · United States (5) · Netherlands (2) · Germany (1) · Hong Kong (1)
Anthony El-Khoueiry (1) · Ardaman Shergill (1) · Bo Zhang (1) · Chao Liu, PhD (1) · G. M. van Dam, MD, PhD (1) · Guohong Han, MD,Ph.D (1) · Haitao Zhao, MD (1) · Jinbo Yue (1) · M. T. de Boer, MD, PhD (1) · Mitesh Borad, MD (1) · Richard Kim (1) · Salah Al-Batran, Prof. Dr. (1)
PMID 20375404, PMID 24769639, PMID 24852116, PMID 26179201, PMID 26598942, PMID 27095655, PMID 27234522, PMID 27806234, PMID 28420720, PMID 28818953, PMID 29341833, PMID 29433850, PMID 29882997, PMID 30515783, PMID 30642373, PMID 30646854, PMID 30755690, PMID 30811474, PMID 31081949, PMID 31403867, PMID 31407173, PMID 31501784, PMID 33198671, PMID 42433279
U10CA032102 (2), P30CA168524 (1), U10CA180821 (1), U10CA180888 (1)